RESEARCH · RESEARCH · #1653
RadOnc-Agent: LLM-orchestrated framework for longitudinal radiotherapy workflows (arXiv:2610.06923v1)
RadOnc-Agent is an agentic AI framework that formalizes radiotherapy into four clinical phases and exposes 26 callable functions via a conversational LLM controller that maps clinical intent to schema-constrained service calls while preserving patient and workflow state. Evaluated on 2,600 single-function requests, 200 synthetic cross-stage scenarios, and 120 workflow instances from 60 de-identified patient records, the system selected the intended function in 98.79% of single-function runs and completed ~96.5–96.7% of cross-stage and real-patient workflows; the authors emphasize these results demonstrate technical feasibility, not clinical correctness or benefit.
KEY POINTS
- RadOnc-Agent is an agentic AI framework that formalizes radiotherapy into four clinical phases and exposes 26 callable functions via a conversational LLM controller that maps clinical intent to schema-constrained service calls while preserving patient and workflow state.
- Evaluated on 2,600 single-function requests, 200 synthetic cross-stage scenarios, and 120 workflow instances from 60 de-identified patient records, the system selected the intended function in 98.79% of single-function runs and completed ~96.5–96.7% of cross-stage and real-patient workflows; the authors emphasize these results demonstrate technical feasibility, not clinical correctness or benefit.
- This paper demonstrates that an LLM-based controller can coordinate heterogeneous radiotherapy tools and preserve longitudinal state to execute multi-stage workflows reliably, indicating a path toward integrated AI orchestration in clinical radiotherapy systems, though it does not prove clinical safety or benefit.
WHY IT MATTERS
This paper demonstrates that an LLM-based controller can coordinate heterogeneous radiotherapy tools and preserve longitudinal state to execute multi-stage workflows reliably, indicating a path toward integrated AI orchestration in clinical radiotherapy systems, though it does not prove clinical safety or benefit.